Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ross Pinkerton

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Paediatrics and Child Health|June 11, 2011
Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approachAndrew S Moore, Ross Norris, Gareth Price, et al.
Pediatric Blood & Cancer|December 6, 2018
Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trialLucas Moreno, Sucheta J Vaidya, Dominik Schrey, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2006
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncologyIsabelle Flandin, Olivier Hartmann, Jean Michon, et al.
Blood|November 30, 2006
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patientsCatherine Patte, Anne Auperin, Mary Gerrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 studyMitchell S Cairo, Richard Sposto, Mary Gerrard, et al.
Blood|December 2, 2006
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsMitchell S Cairo, Mary Gerrard, Richard Sposto, et al.
Psycho-Oncology|December 27, 2017
Do Australian adolescents' and young adults' experiences of cancer care influence their quality of life?Gemma Skaczkowski, Victoria White, Kate Thompson, et al.
British Journal of Haematology|March 29, 2008
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international studyMary Gerrard, Mitchell S Cairo, Claire Weston, et al.
Journal of Pain and Symptom Management|January 10, 2002
The measurement of symptoms in young children with cancer: the validation of the Memorial Symptom Assessment Scale in children aged 7-12John J Collins, Tom D Devine, Gina S Dick, et al.
Blood|November 15, 2012
Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapyMary Gerrard, Ian M Waxman, Richard Sposto, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Paediatrics and Child Health|June 11, 2011
Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approachAndrew S Moore, Ross Norris, Gareth Price, et al.
Pediatric Blood & Cancer|December 6, 2018
Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trialLucas Moreno, Sucheta J Vaidya, Dominik Schrey, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2006
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncologyIsabelle Flandin, Olivier Hartmann, Jean Michon, et al.
Blood|November 30, 2006
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patientsCatherine Patte, Anne Auperin, Mary Gerrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 studyMitchell S Cairo, Richard Sposto, Mary Gerrard, et al.
Blood|December 2, 2006
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsMitchell S Cairo, Mary Gerrard, Richard Sposto, et al.
Psycho-Oncology|December 27, 2017
Do Australian adolescents' and young adults' experiences of cancer care influence their quality of life?Gemma Skaczkowski, Victoria White, Kate Thompson, et al.
British Journal of Haematology|March 29, 2008
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international studyMary Gerrard, Mitchell S Cairo, Claire Weston, et al.
Journal of Pain and Symptom Management|January 10, 2002
The measurement of symptoms in young children with cancer: the validation of the Memorial Symptom Assessment Scale in children aged 7-12John J Collins, Tom D Devine, Gina S Dick, et al.
Blood|November 15, 2012
Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapyMary Gerrard, Ian M Waxman, Richard Sposto, et al.
Pageof 5